The Samaranch Lab is a translational neuroscience laboratory focused on the development of adeno-associated virus (AAV) gene therapies for the central nervous system. Our research includes proof-of-concept experiments to evaluate brain and spinal cord distribution, axonal transport, and cellular specificity of different AAV serotypes after parenchymal and cerebrospinal fluid delivery, as well as the characterization of new capsid-engineered vectors as better tools for the treatment of neurological diseases like Parkinson's disease, Alzheimer's disease, Huntington's disease, MAOA deficiency, AADC deficiency, Nieman-Pick Type A, and GM1-gangliosidosis. Other interests of the lab are the deep understanding of the immunological consequences after AAV delivery into the central nervous system, and the development of new delivery approaches and devices to facilitate the translation of our research from the bench to the clinic.